Jinshi Yayao Waives Pre-emptive Rights in Lingye Pharma Capital Increase, Stake Passively Diluted to 30.12%

Corporate Action
โดย 财中社·Read original
Summary · why it matters

Jinshi Yayao announced that the company has waived its pre-emptive subscription rights in the current capital increase of its associate, Hangzhou Lingye Pharmaceutical Technology Co., Ltd. Lingye Pharma plans to introduce a new strategic investor, Lishui Green Industry Development Fund Co., Ltd., with a capital increase of 40 million yuan and an addition of 1.01 million yuan in registered capital. Before the capital increase, Jinshi Yayao held a 32.43% stake in Lingye Pharma. After the capital increase, its shareholding will be passively diluted to 30.12%. The company's waiver of pre-emptive subscription rights in this capital increase constitutes a related-party transaction.

Impact on stocks 2

Others▼ · 2 stocks

Off-coverage companies 2

杭州领业医药科技有限公司Private▲ Positive
Capitalrelevance

Lingye Pharma is receiving a 40 million yuan capital increase from a new strategic investor.

丽水市绿色产业发展基金有限公司Private▲ Positive
Capitalrelevance

As the new strategic investor, Lishui Green Industry Development Fund is investing 40 million yuan in Lingye Pharma.

© 2026 MarketDXNews